trial · primary record
Rozanolixizumab
Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 113 |
| Primary completion | 2027-07-01 |
| Primary endpoint | For Part A: Time from randomization to first independently centrally adjudicated relapse (TTFR) during the DB Treatment Period |
| Registry ID | NCT05063162 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:36.136Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05063162
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.